APLIF News and Press, Appili Therapeutics Inc From 02/28/22

Funds to advance ATI-1701 to IND submission Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the U.S. Departme...

Appili Therapeutics press release (OTCQX:APLIF): FQ3 GAAP EPS of -C$0.05. Revenue of C$1.4M (+4566.7% Y/Y). For further details see: Appili Therapeutics GAAP EPS of -C$0.05, revenue of C$1.4M

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced its financial and operational results for the third quarter of its fiscal year 202...

Agreement expanded to add European and Latin American markets NDA filing with US FDA for Appili’s ATI-1501 expected later this year Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmac...

Positive one year challenge data builds on previously reported efficacy observed at 28- and 90-day challenge timepoints Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug deve...

Appili Therapeutics (OTCQX:APLIF): 1H GAAP EPS of -$0.30. As of September 30, 2021, the Company had cash and short-term investments of $10.0 million, compared to $16.1 million on March 31, 2021. Press Release For further details see: Appili Therapeutics reports 1H results

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2022, which e...

Appili Therapeutics (OTCQX:APLIF) announces that the company's oral antiviral Avigan/Reeqonus (favipiravir) failed to meet the primary endpoint in a late-stage trial for the treatment of mild-to-moderate COVID-19. The Phase 3 PRESECO (PREventing SEvere COVID-19 Disease) study i...

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the Phase 3 PRESECO (PREventing SEvere COVID-19) clinical trial evaluating or...

AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics - Strategic alliance will accelerate global development of broad spectrum antiviral oral medicine Avigan®/Reeqonus™ (favipiravir) for the treatment of COVID-19 and other infecti...